Investigating the effect of magnesium supplementation on stress and ovulatio

Phase 3

• Conditions: Polycystic Ovary Syndrome.; Polycystic ovarian syndrome; E28.2

• Registration Number: IRCT20091229002924N3
• Lead Sponsor: Bojnourd University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Female
• Target Recruitment: 108

Inclusion Criteria

Infertility for more than a year
Absence of acute and chronic diseases,
Not using medicinal compounds and supplements containing magnesium.
Not taking anti-anxiety and sedative drugs.
Not using drugs, tobacco and alcohol.
Not using relaxation techniques.
Body mass index less than 35,
Magnesium intake less than 75% of the recommended dietary intake

Exclusion Criteria

Pregnancy,
Use of oral contraceptive pills,
Occurrence of any severe stress (for example, divorce or death of a relative),
Personal desire to withdraw from the study during the study,
Consumption of less than 90 out of 112 magnesium supplement tablets or placebo.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To determine the effect of magnesium supplementation on stress and ovulation rate in infertile women with polycystic ovary syndrome. Timepoint: Newton's stress questionnaire first and then 4 weeks after taking the pills and at the end of taking the pills.Vaginal ultrasound at the beginning of the study as an entry criterion and then 4 weeks after taking the pills and then between the 10th and 14th day of the trigger drug cycle. Method of measurement: Ultrasound, Newton stress questionnaire.